GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades
Virchows Archiv · 2025
DOI: 10.1007/s00428-025-04098-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Virchows Archiv, 2025. Verfasst von Hirofumi Watanabe und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Tohoku University Hospital, 1 - 1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980 - 8574, Japan. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Receptors, Somatostatin, Pancreatic Neoplasms, Insulin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radiolabeled glucagon-like peptide 1 (GLP- 1) analog scintigraphy is a new, high-sensitivity imaging method for detecting small insulinomas. Somatostatin receptor scintigraphy (SRS) is an established method for detecting gastroenteropancreatic neuroendocrine tumors. However, small benign insulinomas are difficult to detect using SRS. Furthermore, GLP- 1 receptor (GLP- 1R) expression and SRS results may be inversely correlated. We identified 689 neuroendocrine neoplasms, including pancreatic neuroendocrine tumors (PanNETs) and neuroendocrine neoplasms originating from non-pancreatic sites, and performed GLP- 1R immunostaining. Among the non-insulinoma PanNETs, immunohistochemical insulin or proinsulin positive cases were categorized as Ins pos , and both negative cases as Ins neg . High prevalence of GLP- 1R expression was detected in PanNETs and duodenal NETs (34% and 53%, respectively). Some pulmonary NETs were GLP- 1R positive (9%). In contrast, neither GI-NEC excluding one case nor pulmonary NEC exhibited GLP- 1R expression. The percentage of GLP- 1R positive cases for Ins pos , Ins neg , and insulinoma was 31%, 0%, and 84%, respectively. Among PanNETs, GLP- 1R positive cases showed higher expression of insulin and proinsulin than negative cases. SRS-positive patients showed lower expression levels of insulin, proinsulin, and GLP- 1R than SRS-negative patients. The expression in PanNETs and duodenal NETs may be derived from the expression in their normal counterparts. Insulinoma and Ins pos cases showed GLP- 1R expression. Furthermore, as GLP- 1R-positive patients showed significantly higher expression of insulin and proinsulin than GLP- 1R negative patients, GLP- 1R may also be associated with neoplastic insulin production and GLP- 1 analog scintigraphy may detect subclinical insulinomas. In addition, SRS-negative cases showed significantly higher GLP- 1R expression than SRS-positive cases. These results suggest the application potential of GLP- 1 analog scintigraphy in combination with SRS as a detection tool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Tohoku University Hospital, 1 - 1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980 - 8574, Japan.
- Department of Pathology, Tohoku University Hospital, 1 - 1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980 - 8574, Japan. ffujishima@patholo2.med.tohoku.ac.jp.
- Department of Surgery, Kansai Electric Power Hospital, Osaka, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center, Tokyo, Japan.
- Department of Gastroenterology, Aichi Cancer Center Hospital, Aichi, Japan.
- Department of Pathology and Clinical Laboratories, National Cancer Center, Tokyo, Japan.
Zitieren
APA
Watanabe, H., Fujishima, F., Yamazaki, Y., Imamura, M., Hijioka, S., Hara, K., Kuwahara, T., Yatabe, Y., Sakamoto, K., Shiga, H., Kawaguchi, T., Suzuki, H., Kanbayashi, Y., Ohkoshi, A., Shimada, M., Niikawa, H., Sato, M., Fujio, A., Masui, T., …, & Suzuki, T. (2025). GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades. Virchows Archiv. https://doi.org/10.1007/s00428-025-04098-2
Vancouver
Watanabe H, Fujishima F, Yamazaki Y, Imamura M, Hijioka S, Hara K, et al. GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades. Virchows Archiv. 2025. doi:10.1007/s00428-025-04098-2
BibTeX
@article{Watanabe2025,
author = {Watanabe, Hirofumi and Fujishima, Fumiyoshi and Yamazaki, Yuto and Imamura, Masayuki and Hijioka, Susumu and Hara, Kazuo and Kuwahara, Takamichi and Yatabe, Yasushi and Sakamoto, Kazuhiro and Shiga, Hisashi and Kawaguchi, Tomohiro and Suzuki, Hiroyoshi and Kanbayashi, Yumi and Ohkoshi, Akira and Shimada, Muneaki and Niikawa, Hiromichi and Sato, Mami and Fujio, Atsushi and Masui, Toshihiko and Kasai, Yosuke and Ota, Hideki and Ozawa, Hiroshi and Endo, Hidenori and Unno, Michiaki and Sasano, Hironobu and Suzuki, Takashi},
title = {GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades},
journal = {Virchows Archiv},
year = {2025},
doi = {10.1007/s00428-025-04098-2}
}
EUVIMED